Switching of EBV cycles between latent and lytic states

Reviews in Medical Virology

Volumn 24, Issue 3, 2014, Pages 142-153

  Murata, Takayuki ^a,b   Tsurumi, Tatsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; CALCIUM IONOPHORE; HISTONE; HISTONE DEACETYLASE INHIBITOR; MYOCYTE ENHANCER FACTOR 2; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR SP1; ZINC FINGER PROTEIN;

DRUG EFFECTS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; PATHOGENICITY; PROMOTER REGION; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

CALCIUM IONOPHORES; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONES; HOST-PATHOGEN INTERACTIONS; HUMANS; MEF2 TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; TETRADECANOYLPHORBOL ACETATE; TRANS-ACTIVATORS; VIRUS ACTIVATION; VIRUS LATENCY; ZINC FINGERS;

EID: 84898785158     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1780     Document Type: Review

References (118)

1. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003; 22: 5108-5121.
2. Young LS, Rickinson AB. Epstein-Barr virus: 40years on. Nature Reviews Cancer 2004; 4: 757-768.
3. Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Reviews in Medical Virology 2005; 15: 3-15.
4. Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Reviews in Medical Virology 2005; 15: 149-156.
5. Hammerschmidt W, Sugden B. Replication of Epstein-Barr viral DNA. Cold Spring Harbor Perspectives in Biology 2013; 5: a013029.
6. Hsu M, Wu SY, Chang SS, et al. Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. Journal of Virology 2008; 82: 3679-3688.
7. Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathology International 2010; 60: 337-350.
8. Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas. Seminars in Cancer Biology 2012; 22: 127-136.
9. Bejarano MT, Masucci MG. Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 1998; 92: 4256-4262.
10. Hoebe EK, Le Large TY, Tarbouriech N, et al. Epstein-Barr virus-encoded BARF1 protein is a decoy receptor for macrophage colony stimulating factor and interferes with macrophage differentiation and activation. Viral Immunology 2012; 25: 461-470.
11. Ohashi M, Fogg MH, Orlova N, Quink C, Wang F. An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection. PLoS Pathogens 2012; 8: e1003095.
12. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. The New England Journal of Medicine 2001; 345: 1877-1882.
13. Tsai MH, Raykova A, Klinke O, et al. Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Reports 2013; 5: 458-470.
14. Katsumura KR, Maruo S, Takada K. EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes. Journal of Medical Virology 2012; 84: 504-510.
15. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 850-855.
16. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. Lytic cycle switches of oncogenic human gammaherpesviruses. Advances in Cancer Research 2007; 97: 81-109.
17. Speck SH, Chatila T, Flemington E. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends in Microbiology 1997; 5: 399-405.
18. Sinclair AJ. bZIP proteins of human gammaherpesviruses. The Journal of General Virology 2003; 84: 1941-1949.
19. Reinke AW, Grigoryan G, Keating AE. Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and K-bZIP using coiled-coil arrays. Biochemistry 2010; 49: 1985-1997.
20. Adamson AL, Kenney S. The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. Journal of Virology 1999; 73: 6551-6558.
21. Zerby D, Chen CJ, Poon E, Lee D, Shiekhattar R, Lieberman PM. The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus. Molecular and Cellular Biology 1999; 19: 1617-1626.
22. Lieberman PM, Berk AJ. The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes & Development 1991; 5: 2441-2454.
23. Schepers A, Pich D, Hammerschmidt W. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology 1996; 220: 367-376.
24. Gruffat H, Manet E, Rigolet A, Sergeant A. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Research 1990; 18: 6835-6843.
25. Ragoczy T, Miller G. Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. Journal of Virology 2001; 75: 5240-5251.
26. Adamson AL, Darr D, Holley-Guthrie E, et al. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. Journal of Virology 2000; 74: 1224-1233.
27. Manet E, Gruffat H, Trescol-Biemont MC, et al. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. The EMBO Journal 1989; 8: 1819-1826.
28. Longnecker R, Miller CL. Regulation of Epstein-Barr virus latency by latent membrane protein 2. Trends in Microbiology 1996; 4: 38-42.
29. Flemington E, Speck SH. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. Journal of Virology 1990; 64: 1217-1226.
30. Liu S, Liu P, Borras A, Chatila T, Speck SH. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. The EMBO Journal 1997; 16: 143-153.
31. Liu S, Borras AM, Liu P, Suske G, Speck SH. Binding of the ubiquitous cellular transcription factors Sp1 and Sp3 to the ZI domains in the Epstein-Barr virus lytic switch BZLF1 gene promoter. Virology 1997; 228: 11-18.
32. Murata T, Narita Y, Sugimoto A, Kawashima D, Kanda T, Tsurumi T. Contribution of Myocyte Enhancer Factor 2 (MEF2) Family Transcription Factors to BZLF1 Expression in Epstein-Barr virus Reactivation from Latency. Journal of Virology 2013; 87: 10148-10162.
33. Tsai PF, Lin SJ, Weng PL, et al. Interplay between PKCdelta and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation. Journal of Virology 2011; 85: 2373-2385.
34. Ruf IK, Rawlins DR. Identification and characterization of ZIIBC, a complex formed by cellular factors and the ZII site of the Epstein-Barr virus BZLF1 promoter. Journal of Virology 1995; 69: 7648-7657.
35. Wang YC, Huang JM, Montalvo EA. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 1997; 227: 323-330.
36. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. Journal of Virology 2007; 81: 7363-7370.
37. Sun CC, Thorley-Lawson DA. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. Journal of Virology 2007; 81: 13566-13577.
38. McDonald C, Karstegl CE, Kellam P, Farrell PJ. Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency. The Journal of General Virology 2010; 91: 622-629.
39. Fahmi H, Cochet C, Hmama Z, Opolon P, Joab I. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. Journal of Virology 2000; 74: 5810-5818.
40. Liang CL, Chen JL, Hsu YP, Ou JT, Chang YS. Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through cooperativity of Smads and c-Jun/c-Fos proteins. The Journal of Biological Chemistry 2002; 277: 23345-23357.
41. Iempridee T, Das S, Xu I, Mertz JE. Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BZLF1 gene. Journal of Virology 2011; 85: 7836-7848.
42. Jiang JH, Wang N, Li A, et al. Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. Journal of Clinical Virology 2006; 37: 98-103.
43. Hong GK, Kumar P, Wang L, et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. Journal of Virology 2005; 79: 13984-13992.
44. Cayrol C, Flemington EK. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1. Journal of Virology 1995; 69: 4206-4212.
45. Iwakiri D, Takada K. Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. Journal of Immunology 2004; 172: 1561-1566.
46. Oussaief L, Hippocrate A, Ramirez V, et al. Phosphatidylinositol 3-kinase/Akt pathway targets acetylation of Smad3 through Smad3/CREB-binding protein interaction: contribution to transforming growth factor beta1-induced Epstein-Barr virus reactivation. The Journal of Biological Chemistry 2009; 284: 23912-23924.
47. Flemington E, Speck SH. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. Journal of Virology 1990; 64: 1227-1232.
48. Yin Q, Jupiter K, Flemington EK. The Epstein-Barr virus transactivator Zta binds to its own promoter and is required for full promoter activity during anti-Ig and TGF-beta1 mediated reactivation. Virology 2004; 327: 134-143.
49. Chen CC, Yang YC, Wang WH, Chen CS, Chang LK. Enhancement of Zta-activated lytic transcription of Epstein-Barr virus by Ku80. The Journal of General Virology 2011; 92: 661-668.
50. Murata T, Sato Y, Nakayama S, et al. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein. The Journal of Biological Chemistry 2009; 284: 8033-8041.
51. Kraus RJ, Mirocha SJ, Stephany HM, Puchalski JR, Mertz JE. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus. Journal of Virology 2001; 75: 867-877.
52. Kraus RJ, Perrigoue JG, Mertz JE. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. Journal of Virology 2003; 77: 199-207.
53. Yu X, Wang Z, Mertz JE. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathogens 2007; 3: e194.
54. Ellis AL, Wang Z, Yu X, Mertz JE. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. Journal of Virology 2010; 84: 6139-6152.
55. Murata T, Noda C, Saito S, et al. Involvement of Jun Dimerization Protein 2 (JDP2) in the Maintenance of Epstein-Barr Virus Latency. The Journal of Biological Chemistry 2011; 286: 22007-22016.
56. Liu P, Liu S, Speck SH. Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. Journal of Virology 1998; 72: 8230-8239.
57. Yu X, McCarthy PJ, Lim HJ, et al. The ZIIR element of the Epstein-Barr virus BZLF1 promoter plays a central role in establishment and maintenance of viral latency. Journal of Virology 2011; 85: 5081-5090.
58. Montalvo EA, Cottam M, Hill S, Wang YJ. YY1 binds to and regulates cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter. Journal of Virology 1995; 69: 4158-4165.
59. Zhang Q, Wang YC, Montalvo EA. Smubp-2 represses the Epstein-Barr virus lytic switch promoter. Virology 1999; 255: 160-170.
60. Thomas C, Dankesreiter A, Wolf H, Schwarzmann F. The BZLF1 promoter of Epstein-Barr virus is controlled by E box-/HI-motif-binding factors during virus latency. The Journal of General Virology 2003; 84: 959-964.
61. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 1994; 79: 1137-1146.
62. Gao X, Tajima M, Sairenji T. Nitric oxide down-regulates Epstein-Barr virus reactivation in epithelial cell lines. Virology 1999; 258: 375-381.
63. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 1992; 6: 3051-3064.
64. Brune B, von Knethen A, Sandau KB. Nitric oxide (NO): an effector of apoptosis. Cell Death and Differentiation 1999; 6: 969-975.
65. Murata T, Hotta N, Toyama S, et al. Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase. The Journal of Biological Chemistry 2010; 285: 23925-23935.
66. Sista ND, Barry C, Sampson K, Pagano J. Physical and functional interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid receptors RAR alpha and RXR alpha. Nucleic Acids Research 1995; 23: 1729-1736.
67. Sista ND, Pagano JS, Liao W, Kenney S. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 3894-3898.
68. Gutsch DE, Holley-Guthrie EA, Zhang Q, et al. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Molecular and Cellular Biology 1994; 14: 1939-1948.
69. Robinson AR, Kwek SS, Kenney SC. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathogens 2012; 8: e1002516.
70. Raver RM, Panfil AR, Hagemeier SR, Kenney SC. The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. Journal of Virology 2013; 87: 8053-8063.
71. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. NF-kappaB inhibits gammaherpesvirus lytic replication. Journal of Virology 2003; 77: 8532-8540.
72. Liu SF, Wang H, Lin XC, et al. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells. Cell Biology International 2008; 32: 1006-1013.
73. Li Y, Zhang Y, Fu M, et al. Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma. Molecular Medicine Reports 2012; 6: 477-482.
74. Saito S, Murata T, Kanda T, et al. Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-kappaB signaling during productive replication. Journal of Virology 2013; 87: 4060-4070.
75. Konforte D, Paige CJ. Interleukin-21 regulates expression of the immediate-early lytic cycle genes and proteins in Epstein-Barr virus infected B cells. Virus Research 2009; 144: 339-343.
76. Daigle D, Megyola C, El-Guindy A, et al. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. Journal of Virology 2010; 84: 993-1004.
77. Chen H, Lee JM, Zong Y, et al. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. Journal of Virology 2001; 75: 2929-2937.
78. Chen H, Hutt-Fletcher L, Cao L, Hayward SD. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. Journal of Virology 2003; 77: 4139-4148.
79. Kis LL, Takahara M, Nagy N, Klein G, Klein E. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 2006; 107: 2928-2935.
80. Kis LL, Salamon D, Persson EK, et al. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 872-877.
81. Johansson P, Jansson A, Ruetschi U, Rymo L. Nuclear factor-kappaB binds to the Epstein-Barr virus LMP1 promoter and upregulates its expression. Journal of Virology 2009; 83: 1393-1401.
82. Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Seminars in Cancer Biology 2001; 11: 435-444.
83. Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Seminars in Cancer Biology 2002; 12: 473-487.
84. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995; 10: 549-560.
85. Paine E, Scheinman RI, Baldwin AS Jr, Raab-Traub N. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. Journal of Virology 1995; 69: 4572-4576.
86. Gires O, Kohlhuber F, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. The EMBO Journal 1999; 18: 3064-3073.
87. Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. Journal of Virology 2003; 77: 5000-5007.
88. Murata T, Iwata S, Siddiquey MN, et al. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PloS One 2013; 8: e63566.
89. Gao X, Ikuta K, Tajima M, Sairenji T. 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. Virology 2001; 286: 91-99.
90. Goswami R, Gershburg S, Satorius A, Gershburg E. Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus. Antiviral Research 2012; 96: 296-304.
91. Nanbo A, Terada H, Kachi K, Takada K, Matsuda T. Roles of cell signaling pathways in cell-to-cell contact-mediated Epstein-Barr virus transmission. Journal of Virology 2012; 86: 9285-9296.
92. Fernandez AF, Rosales C, Lopez-Nieva P, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Research 2009; 19: 438-451.
93. Woellmer A, Arteaga-Salas JM, Hammerschmidt W. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression. PLoS Pathogens 2012; 8: e1002902.
94. Murata T, Kondo Y, Sugimoto A, et al. Epigenetic Histone Modification of Epstein-Barr Virus BZLF1 Promoter during Latency and Reactivation in Raji Cells. Journal of Virology 2012; 86: 4752-4761.
95. Countryman JK, Gradoville L, Miller G. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. Journal of Virology 2008; 82: 4706-4719.
96. Murata T, Tsurumi T. Epigenetic modification of the Epstein-Barr virus BZLF1 promoter regulates viral reactivation from latency. Frontiers in Genetics 2013; 4: 53.
97. Ramasubramanyan S, Osborn K, Flower K, Sinclair AJ. Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome. Journal of Virology 2012; 86: 1809-1819.
98. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nature Genetics 2004; 36: 1099-1104.
99. Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, Kenney SC. Methylation-dependent binding of the Epstein-Barr virus BZLF1 protein to viral promoters. PLoS Pathogens 2009; 5: e1000356.
100. Johannsen E, Luftig M, Chase MR, et al. Proteins of purified Epstein-Barr virus. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 16286-16291.
101. Wen W, Iwakiri D, Yamamoto K, Maruo S, Kanda T, Takada K. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. Journal of Virology 2007; 81: 1037-1042.
102. White RE, Groves IJ, Turro E, Yee J, Kremmer E, Allday MJ. Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PloS One 2010; 5: e13979.
103. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 1919-1924.
104. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathogens 2010; 6: e1000951.
105. Sato Y, Tsurumi T. Genome guardian p53 and viral infections. Reviews in Medical Virology 2013; 23: 213-220.
106. Sato Y, Shirata N, Murata T, et al. Transient increases in p53-responsible gene expression at early stages of Epstein-Barr virus productive replication. Cell Cycle 2010; 9: 807-814.
107. Sato Y, Kamura T, Shirata N, et al. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathogens 2009; 5: e1000530.
108. Sato Y, Shirata N, Kudoh A, et al. Expression of Epstein-Barr virus BZLF1 immediate-early protein induces p53 degradation independent of MDM2, leading to repression of p53-mediated transcription. Virology 2009; 388: 204-211.
109. Tarakanova VL, Leung-Pineda V, Hwang S, et al. Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host & Microbe 2007; 1: 275-286.
110. Chang YH, Lee CP, Su MT, et al. Epstein-Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality. PloS One 2012; 7: e39217.
111. Wu CC, Liu MT, Chang YT, et al. Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Research 2010; 38: 1932-1949.
112. Kudoh A, Fujita M, Zhang L, et al. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. The Journal of Biological Chemistry 2005; 280: 8156-8163.
113. Daikoku T, Kudoh A, Sugaya Y, et al. Postreplicative mismatch repair factors are recruited to Epstein-Barr virus replication compartments. The Journal of Biological Chemistry 2006; 281: 11422-11430.
114. Kudoh A, Iwahori S, Sato Y, et al. Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments. Journal of Virology 2009; 83: 6641-6651.
115. Sinclair A, Yarranton S, Schelcher C. DNA-damage response pathways triggered by viral replication. Expert Reviews in Molecular Medicine 2006; 8: 1-11.
116. Kudoh A, Fujita M, Kiyono T, et al. Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. Journal of Virology 2003; 77: 851-861.
117. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. Journal of Virology 2004; 78: 1893-1902.
118. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-2578.